UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

The role of Tc-99m-depreotide in the management of neuroendocrine tumours

Shah, T; Kulakiene, I; Quigley, AM; Warbey, VS; Srirajaskanthan, R; Tournpanakis, C; Hochhauser, D; ... Caplin, ME; + view all (2008) The role of Tc-99m-depreotide in the management of neuroendocrine tumours. NUCLEAR MEDICINE COMMUNICATIONS , 29 (5) 436 - 440.

Full text not available from this repository.

Abstract

Background. In-111-pentetreotide scan (OctreoScan) is a widely available agent with high sensitivity for imaging neuroendocrine tumours. Negative In-111-pentetreoticle poses diagnostic as well as therapeutic problems in terms of staging and consideration of targeted radionuclide therapy.Aim To assess the role of Tc-99m-depreotide in patients with negative or weakly positive OctreoScan (Krenning score <= 1; measured on a scale range 0-4). To determine the usefulness of Tc-99m-depreotide scintigraphy for highlighting lesions that may be missed by OctreoScan and/or CT/MRI imaging.Study design Prospective analysis of 25 patients with neuroendocrine tumours, with negative or weakly positive In-111-pentetreoticle scans, who were consecutively enrolled to undergo In-111-pentetreotide and Tc-99m-depreotide imaging. The results were compared with either CT or MRI scans.Results Histology was available for 20 of 25 patients: of these 40% had high-grade tumours (cellular proliferation marker Ki-67 score >20%), a further 35% had intermediate-grade tumours (Ki-67 2-20%), and the remaining 25% had low-grade tumours (Ki-67 <2%). Fifty-two percent of patients had completely negative and 48% had weakly positive OctreoScan results. Thirty-two percent of these same patients had significantly positive Tc-99m-depreotide scans (Krenning score >= 2), with the histology demonstrating intermediate-grade or high-grade tumours.Conclusion Tc-99m-depreotide imaging has low sensitivity but is useful in a one-third of OctreoScan-negative patients, displaying significantly better uptake than In-111-pentetreotide in this patient group. It aids diagnosis by highlighting lesions not seen by OctreoScan and/or CT/MRI imaging, and can possibly identify a group of patients amenable to therapy with radionuclide agents, such as SOM230, targeting somatostatin receptor subtypes 2, 3 and 5.

Type: Article
Title: The role of Tc-99m-depreotide in the management of neuroendocrine tumours
Location: Los Angeles, CA
Additional information: Invalid ISBN Tumour Unit, Dept Nucl Med, London NW3 2QG, England read from Web of Science.
Keywords: neuroendocrine tumour, Tc-99m-depreotide scan, In-111-pentetreotide scan, somatostatin receptor scintigraphy, CELL-PROLIFERATION, SOMATOSTATIN, INHIBITION, SSTR2
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
URI: http://discovery.ucl.ac.uk/id/eprint/91552
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item